The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Why should chromosome 1 abnormalities be assessed in all patients with MM?
Featured:
Timothy M. SchmidtDuring the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked, why should chromosome 1 abnormalities be assessed in all patients with multiple myeloma (MM)?
Why should chromosome 1 abnormalities be assessed in all patients with MM?
In this video, Schmidt discusses the importance and utility of assessing chromosome 1 abnormalities for prognosis of high-risk MM patients. He also highlights the importance of identifying patients with chromosomal abnormalities early.